ROIV News and Press, Roivant Sciences Ltd. From 01/12/26

2026-01-12 14:30:00 ET Listen here or on the go via Apple Podcasts and Spotify Sifting the World's Chris DeMuth Jr. discusses value investing and his top thoughts for the new year (0:25). 2 stocks: Willis Lease and FTAI Aviation (3:00). Relevant risks and metrics...

2026-01-08 10:42:26 ET Roivant Sciences Ltd. (ROIV) Q2 2025 Earnings Call November 10, 2025 8:00 AM EST... Read the full article on Seeking Alpha For further details see: Roivant Sciences Ltd. (ROIV) Q2 2025 Earnings Call Transcript

2025-12-22 23:25:00 ET The following segment was excerpted from the Goldman Sachs Mid Cap Growth Fund Q3 2025 Commentary. ... Read the full article on Seeking Alpha For further details see: Goldman Sachs Mid Cap Growth Fund Q3 2025 Investment Update

2025-12-17 12:29:56 ET Fast Facts About the Direxion Daily S&P Biotech Bull 3X ETF Read the full article on Seeking Alpha For further details see: LABU: The Risks And Rewards Of A Leveraged Biotechnology ETF

2025-12-14 23:48:00 ET This article is part of a series that provides an ongoing analysis of the changes made to David Einhorn’s Greenlight Capital 13F portfolio on a quarterly basis. It is based on Einhorn’s regulatory 13F Form filed on 11/14/2025. Please visit our ...

2025-12-12 18:12:53 ET Roivant Sciences Ltd. (ROIV) Analyst/Investor Day December 11, 2025 8:00 AM EST Company Participants Keyur Parekh Matthew Gline - CEO & Director Benjamin Zimmer Richard Pulik - Chief Financial Officer Frank Torti Eric Ve...

2025-12-12 16:28:31 ET The last time I spoke about Immunovant ( IMVT ) it was with respect to a Seeking Alpha article entitled " Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward ". With respect to this article, I noted that the company was ...

2025-12-12 09:15:03 ET H.C. Wainwright analyst issues BUY recommendation for ROIV on December 12, 2025 02:05PM ET. The previous analyst recommendation was Buy. ROIV was trading at $21.4917 at issue of the analyst recommendation. The overall analyst consensus : BUY. C...

Roivant enters new phase of corporate journey with 3+ launches, 4+ NDA/BLA filings, 8+ pivotal and 3+ proof-of-concept study readouts expected over the next three years Highlighting clinical execution, Roivant announces positive updates to timing guidance across four key programs: Brepoci...

Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – Scientists have engineered breakthrough cell therapies that can be mass-produced and stored ready-to-use, addressing key barriers in treatment access and cost [1] . Resear...